Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab in pediatric colchicine-resistant/intolerant FMF
NCT01148797Phase 2Completed
- Sponsor
- Novartis
- Start
- Dec 2010
- Primary completion
- Feb 2012
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of canakinumab in Familial Mediterranean fever (FMF), sponsored by Novartis. Started Dec 2010; status: completed.
02
Drugs
canakinumab
03
Conditions
Familial Mediterranean fever (FMF)
Beyond the preview
Go deeper on NCT01148797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01148797.